TABLE 1.
Baseline Characteristics
| Characteristic | Patient groupa
|
P value | |
|---|---|---|---|
| Clopidogrel (n=40) | Control (n=80) | ||
| Age, y | 82.0 (8.7) | 82.3 (8.3) | .68 |
| Men | 18 (45) | 36 (45) | 1.00 |
| Raceb | 1.00 | ||
| White | 37 (93) | 76 (95) | |
| Not white | 0 (0) | 1 (1) | |
| Not reported | 3 (7) | 3 (4) | |
| Previous coronary stent | 13 (33) | 5 (6) | <.001 |
| ASA score | 1.00 | ||
| 3 | 32 (80) | 64 (80) | |
| 4 | 8 (20) | 16 (20) | |
| Type of fracture | .71 | ||
| Femoral neck | 20 (50) | 38 (48) | |
| Intertrochanteric | 15 (38) | 36 (45) | |
| Subtrochanteric | 2 (5) | 2 (3) | |
| More than one | 3 (8) | 4 (5) | |
| Type of fracture repair | .97 | ||
| Screws | 4 (10) | 10 (13) | |
| Plate & screws | 9 (23) | 17 (21) | |
| Intramedullary rod | 12 (30) | 25 (31) | |
| Hemiarthroplasty | 15 (38) | 28 (35) | |
| Anesthesia type | .18 | ||
| Regional | 0 (0) | 6 (8) | |
| General | 40 (100) | 74 (93) | |
| Laboratory values at admission | |||
| Hemoglobin, g/dL | 12.0 (1.5) | 12.5 (1.6) | .14 |
| Platelets, ×109/L | 226 (63) | 234 (89) | .85 |
| Creatinine, mg/dL | 1.5 (1.1) | 1.2 (0.6) | .34 |
| INR | 1.0 (0.1) (n=34) | 1.3 (0.7) (n=69) | .83 |
| aPTT, s | 26.5 (4.4) (n=25) | 27.0 (4.3) (n=54) | .99 |
| Medications at admission | |||
| Warfarin | 1 (3) | 15 (19) | .01 |
| Aspirin | 26 (65) | 50 (63) | .79 |
| Time from admission to surgery, d | 1.1 (0.7) | 1.3 (1.3) | .77 |
| Thromboembolic prophylaxis | 40 (100) | 79 (99) | 1.00 |
| Warfarin | 2 (5) | 17 (21) | .02 |
| Aspirin | 0 (0) | 4 (5) | .30 |
| LMWH | 27 (68) | 49 (61) | .50 |
| Unfractionated heparin | 8 (20) | 7 (9) | .08 |
| SCD use | 38 (95) | 75 (94)c | .77 |
| Other | 0 (0) | 1 (1) | 1.00 |
| Dose reduction of DVT prophylaxis | 16 (40) | 39 (49) | .36 |
aPTT = activated partial thromboplastin time; ASA = American Society of Anesthesiologists; DVT = deep venous thrombosis; INR = international normalized ratio; LMWH = low-molecularweight heparin; SCD = sequential compression device.
a
Values are mean (SD) or No. of patients (%).
b
Race was self-reported.
c
One patient received only SCDs as the thromboembolic prophylaxis regimen.